ESMO Immuno-Oncology Congress 2024: Event Announcement
en-GBde-DEes-ESfr-FR

ESMO Immuno-Oncology Congress 2024: Event Announcement


Lugano, Switzerland, 2 December 2024 – The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology. Topics will include new therapeutic opportunities, interpretation of recent data and management of treatment-related toxicities.

Programme highlights
  • Results from a phase 3 trial on gut microbiota as a potential biomarker for chemo-immunotherapy in non-small cell lung cancer and novel data on the role of gut microbiota in immunotherapy efficacy and toxicity.
  • New insights on the efficacy of early immunotherapy in patients with unresectable non-small cell lung cancer or who refused surgery.
    • Related content: Abstract 117O
  • Novel findings on the potential of liquid biopsy and circulating tumor DNA in immunotherapy: new insights into the biological characteristics of individual patients.
  • Data on potential treatment approaches that integrate immunotherapy and (chemo)radiotherapy to improve outcomes for patients with non-small cell lung cancer.
    • Related content: Abstracts 65O, 66MO
  • Insights on scientific advances in immuno-oncology in 2024, with a focus on immuno-biology and clinical applications.

Keynote Lectures
The results of the studies presented at the congress will be published online as a supplement to IOTECH. The abstract titles and sessions can be viewed in the online programme.

Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO Immuno-Oncology Congress 2024. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditations will not be available.

Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Regions: Europe, Switzerland
Keywords: Health, Medical, Public Dialogue - health

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Referenzen

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Wir arbeiten eng zusammen mit...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement